Urologic Issues in the Renal Transplant Patient

Chapter
First Online:

Abstract

Patients with end stage renal disease (ESRD) or a history of renal transplantation frequently suffer from or are at risk for a variety of urological illnesses. Urologists are frequently involved in the preoperative evaluation for renal transplantation as well as management of postoperative complications. Many urological issues that affect the general population including erectile dysfunction, bladder, prostate, and renal malignancy, calculi, and hydronephrosis require special consideration in the ESRD and renal transplant populations. Having an understanding of the urological issues faced by this population allows for a more effective multidisciplinary approach to the transplant patient. This chapter focuses on common urological illnesses and aspects of their management that are specific to the ESRD or renal transplant patient.

Keywords

Prostate Cancer Erectile Dysfunction Renal Mass Autosomal Dominant Polycystic Kidney Disease Localize Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Saenz de Tejada I, Goldstein I, Azadzoi K, Krane R, Cohen RA. Impaired neurogenic and endothelium‐mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med. 1989;320:1025–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Procci WR, Goldstein DA, Adelstein J, Massry SG. Sexual dysfunction in the male patient with uremia: a reappraisal. Kidney Int. 1981;19:317–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Ayub W, Fletcher S. End stage renal disease and erectile dysfunction: is there any hope? Nephrol Dial Transplant. 2000;15:1525–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Ahmad M, Rafiuddin Q, Hassan U, Ahmad A, Husain S. Impact of renal transplantation on erectile dysfunction due to chronic renal failure in male patients. J Ayub Med Coll Abbottabad. 2009;21: 69–71.PubMedGoogle Scholar
  5. 5.
    Zamd M, Gharibi MB, Ramadni B, Zaid D. Sexual dysfunction in male patients undergoing HD in Morocco. Saudi J Kidney Dis Transpl. 2005;16:33–9.PubMedGoogle Scholar
  6. 6.
    Dean R, Lue T. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;21:279–81.Google Scholar
  7. 7.
    Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Mallick HN, Manchanda SK, Kumar VM. Sensory modulation of the medial preoptic area neuronal activity by dorsal penile nerve stimulation in rats. J Urol. 1994;151:759.PubMedGoogle Scholar
  9. 9.
    Lim V, Fang V. Gonadal dysfunction in uremic men. A study of the hypothalamo-pituitary testicular axis before and after renal transplantation. Am J Med. 1975;58:655–62.PubMedCrossRefGoogle Scholar
  10. 10.
    McCulloch DK, Young RJ, Prescott RJ, Campbell IW, Clarke BF. The natural history of impotence in diabetic men. Diabetologia. 1984;26:437–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int. 2001;87: 402–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Gazzaruso C, Solerte SB, Pujia A. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol. 2008;51:2040–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Ma RCW, SO WY, Yang X. Erectile dysfunction predicts coronary heart disease in Type 2 diabetes. J Am Coll Cardiol. 2008;51: 2045–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Fagelman E, Fagelman A, Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology. 2001;57:1141–4.PubMedCrossRefGoogle Scholar
  15. 15.
    El-Galley R, Rutland H, Talic R, Keane T, Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol. 2001;166:927–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Niwa T, Yamamoto S, Saito M, Shiraga T, Takagi A. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku Zasshi. 2007;127:209–16.PubMedCrossRefGoogle Scholar
  17. 17.
    Raina R, Agarwal A, Ausmundson S, Mansour D, Zippe CD. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM analysis. Int J Impot Res. 2005;17:86–90.PubMedCrossRefGoogle Scholar
  18. 18.
    McMahon CG. Comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, prostaglandin E1 alone and a combination of all three in the management of impotence. Int J Impot Res. 1991;3:133–42.Google Scholar
  19. 19.
    Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. 1974;2:80–2.CrossRefGoogle Scholar
  20. 20.
    Rowe SJ, Montague DK, Steinmuller DR, Lakin MM, Novick AC. Treatment of organic impotence with penile prosthesis in renal transplant patients. Urology. 1993;41:16–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Cuellar DC, Sklar GN. Penile prosthesis in the organ transplant recipient. Urology. 2001;57:138–41.PubMedCrossRefGoogle Scholar
  22. 22.
    Gallagher M, Kelly P, Jardine M, Perkovic V, Cass A, Craig J, Eris J, Webster A. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol. 2010;21:852–8.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Buzzeo BD, Heisey DM, Messsing EM. Bladder cancer in renal transplant recipients. Urology. 1997;50:525–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Wu MJ, Lian JD, Yang CR, Cheng CH, Chen CH, Lee WC, Shu KH, Tang MJ. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis. 2004;43:1091–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant. 2001;16:1545.PubMedCrossRefGoogle Scholar
  26. 26.
    Doublet JD, Peraldi MN, Gattegno B. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol. 1997;158:42–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Palou J, Angerri O, Segarra J, et al. Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation. 2003;76:1514–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Lang H, Petriconi R, Wenderoth U, Volkmer B, Hautmann R, Gschwend J. Orthotopic ileal neobladder reconstruction in patients with bladder cancer following renal transplantation. J Urol. 2005;173:881–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Giessing M, Türk I, Schoenberger B, Loening S. Orthotopic neobladder after kidney transplantation in a male patient with recurring urothelial carcinoma and renal cancer. J Urol. 2001;166:1383.PubMedCrossRefGoogle Scholar
  30. 30.
    Karam G, Hétet JF, Maillet F. Late ureteral stenosis following renal transplantation: risk factors and impact on patient and graft survival. Am J Transplant. 2006;6:352.PubMedCrossRefGoogle Scholar
  31. 31.
    Masahiko H, Kazunari T, Tokumoto T, et al. Comparative study of urosurgical complications in renal transplantation: intravesical versus extravesical ureterocystoneostomy. Transplant Proc. 2000;32: 1844.PubMedCrossRefGoogle Scholar
  32. 32.
    Holton MR, Van Zijl PS, Oberle WT, Jacobs SC, Sklar GN. Complete urinary tract extirpation: the University of Maryland experience. Urology. 2006;68:65–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277.PubMedCrossRefGoogle Scholar
  34. 34.
    Loeb S, Carter HB. Early detection, diagnosis, and staging of prostate cancer. In: Wein AJ et al., editors. Campbell-Walsh urology. 10th ed. Philadelphia, PA: Elsevier Saunders; 2012. p. 2763–70.CrossRefGoogle Scholar
  35. 35.
    Moyer VA. Screening of prostate cancer: US Preventive Task force recommendation statement. Ann Intern Med. 2012;157:120–34.PubMedCrossRefGoogle Scholar
  36. 36.
    Breyer BN, Whitson JM, Freise CE, Meng MV. Prostate cancer screening and treatment in the transplant population: current status and recommendations. J Urol. 2009;181:2018–26.PubMedCrossRefGoogle Scholar
  37. 37.
    Chen CJ, Heldt JP, Anderson KM, et al. Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease. J Urol. 2012;187:2061–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Muruve NA, Shoskes DA. Genitourinary malignancies in solid organ transplant recipients. Transplantation. 2005;80:709–16.PubMedCrossRefGoogle Scholar
  39. 39.
    Secin FP, Carver B, Kattan MW, Eastham JA. Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate? Transplantation. 2004;78:710–2.PubMedCrossRefGoogle Scholar
  40. 40.
    Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant. 1997;2:14–7.PubMedGoogle Scholar
  41. 41.
    Kleinclauss F, Gigante M, Neuzillet Y, et al. Prostate cancer in renal transplant recipients. Nephrol Dial Transplant. 2008;23:2374–80.PubMedCrossRefGoogle Scholar
  42. 42.
    Pollard M. Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A. Cancer Lett. 1997;111:221–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Coombs CC, Hertzfeld K, Barrett W. Outcomes in transplant patients undergoing brachytherapy for prostate cancer. Am J Clin Oncol. 2012;35:40–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Antonopoulos IM, Nahas WC, Piovesan AC, et al. Radical retropubic prostatectomy for localized prostate cancer in renal transplant patients. Urology. 2008;72:1362–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Smith DL, Jellison FC, Heldt JP, et al. Robot-assisted radical prostatectomy in patients with previous renal transplantation. J Endourol. 2011;10:1643–7.CrossRefGoogle Scholar
  46. 46.
    Parker J, Spiess PE. Current and emerging bladder cancer urinary biomarkers. ScientificWorldJournal. 2011;11:1103–12.PubMedCrossRefGoogle Scholar
  47. 47.
    Moreno JA, Martin-Cleary C, Gutierrez E, et al. Haematuria: the forgotten CKD factor? Nephrol Dial Transplant. 2012;27:28–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Sharma AK, Sunil S, Rowlands P, Bakran A. Pseudoaneurysm with severe haematuria in renal allograft after renal biopsy treated by percutaneous embolization. Nephrol Dial Transplant. 2002;17: 934–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;10:1277–86.CrossRefGoogle Scholar
  50. 50.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71.PubMedCrossRefGoogle Scholar
  51. 51.
    Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence and renal cancers. Medicine. 1990;69:217.PubMedCrossRefGoogle Scholar
  52. 52.
    United Stated Renal Data System. USRDS 2007 annual data report. Bethesda, MD: National Institute of Health (NIH), US Department of Health and Human Services (DHHS); 2007.Google Scholar
  53. 53.
    Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–62.PubMedCrossRefGoogle Scholar
  54. 54.
    Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Thomsen H. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16:2619–21.Google Scholar
  56. 56.
    Suson K, Sausville J, Sense A, Phelan M. Native nephrectomy for renal cell carcinoma in transplant recipients. Transplantation. 2011;91:1376–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Leveridge M, Musquera M, Evans A, et al. Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. J Urol. 2011;196:219–23.CrossRefGoogle Scholar
  58. 58.
    Sankari B, Chueh S. Simultaneous laparoendoscopic single-site radical nephrectomy for native kidney and open nonischemic partial nephrectomy to treat concomitant renal cell carcinoma in native and transplant kidneys and to preserve allograft function. Urology. 2012;79:139–44.PubMedCrossRefGoogle Scholar
  59. 59.
    Barama A, St-Louis G, Nicolet V, et al. Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant. 2005;5:3015–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Cox A, Nguan C, Luke P. Partial nephrectomy for renal cell carcinoma in long term renal allografts: operative and post-operative considerations. Can J Urol. 2005;12:2887–90.PubMedGoogle Scholar
  61. 61.
    Gabow P. Autosomal dominant polycystic kidney disease. N Engl J Med. 1993;329:332.PubMedCrossRefGoogle Scholar
  62. 62.
    Parfrey P, Bear J, Morgan J, et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med. 1990;323:1085.PubMedCrossRefGoogle Scholar
  63. 63.
    Fuller T, Brennan T, Feng S, Kang SM, et al. End stage polycystic kidney disease: indications and timing of native nephrectomy relative to kidney transplantation. J Urol. 2005;174:2284.PubMedCrossRefGoogle Scholar
  64. 64.
    Ismail H, Fletcher S, Kaouk J, Derweesh I, et al. Simultaneous vs. sequential laparoscopic bilateral nephrectomy and renal transplantation. Transplantation. 2005;80:1124.PubMedCrossRefGoogle Scholar
  65. 65.
    Glassman D, Nipkow L, Bartlett S, Jacob S. Bilateral nephrectomy with concomitant renal graft transplantation for autosomal dominant polycystic kidney disease. J Urol. 2000;164:661.PubMedCrossRefGoogle Scholar
  66. 66.
    Kramer A, Sausville J, Haririan A, Bartlett S, et al. Simultaneous bilateral native nephrectomy and living donor renal transplantation are successful for polycystic kidney disease: The University of Maryland experience. Urology. 2009;181:724–8.CrossRefGoogle Scholar
  67. 67.
    Klingler H, Kramer G, Lodde M, Marberger M. Urolithiasis in allograft kidneys. Urology. 2002;59:344–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Stavodimos K, Adamis S, Tyritis S, Georgios Z, Constantinides C. Renal transplant lithiasis: analysis of our series and review of the literature. J Endourol. 2012;26:38–44.CrossRefGoogle Scholar
  69. 69.
    Li S, Wang Q, Chen W. Treatment of urinary lithiasis following kidney transplantation with extracorporeal shock-wave lithotripsy. Chin Med J. 2011;124:1431–4.PubMedGoogle Scholar
  70. 70.
    Markic D, Valencic M, Grskovic A, et al. Extracorporeal shockwave lithotripsy of ureteral stone in a patient with en bloc kidney transplantation: a case report. Transplant Proc. 2011;43:2110–2.PubMedCrossRefGoogle Scholar
  71. 71.
    Hyams E, Marien T, Quirouet A, Andonian S, Shah O, Matlaga B. Ureteroscopy for transplant lithiasis. J Endourol. 2012;7:819–22.CrossRefGoogle Scholar
  72. 72.
    Krambeck A, LeRoy A, Patterson D, Gettman MT. Percutaneous nephrolithotomy success in the transplanted kidney. J Urol. 2009;180:2545–9.CrossRefGoogle Scholar
  73. 73.
    Wyatt J, Kolettis P, Burns J. Treatment outcomes for percutaneous nephrolithotomy in renal allografts. J Endourol. 2009;11:1821–4.CrossRefGoogle Scholar
  74. 74.
    Jones JW, Hunter DW, Matas AJ. Percutaneous treatment of ureteral strictures after renal transplant. Transplantation. 1993;55:1193–4.PubMedCrossRefGoogle Scholar
  75. 75.
    Liberman SF, Keller FS, Barry JM, et al. Percutaneous antegrade transluminal ureteroplasty for renal allograft ureteral stenosis. J Urol. 1982;128:122–4.Google Scholar
  76. 76.
    Shoskes D, Hanbury D, Cranston D, et al. Urological complications in 1,000 consecutive renal transplants. J Urol. 1995;153:18–21.PubMedCrossRefGoogle Scholar
  77. 77.
    Schwartz BF, Chatman JR, Bretan P, et al. Treatment of refractory kidney transplant ureteral strictures using balloon cautery endoureterotomy. Urology. 2001;58:536–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Dubovsky EV, Russel CD, Bischof-Delaloye A, et al. Report of the radionuclides in nephrourology committee for evaluation of transplanted kidney (review of techniques). Semin Nucl Med. 1999;29:175–88.PubMedCrossRefGoogle Scholar
  79. 79.
    Jaskowski A, Jones RM, Murie JA, et al. Urological complications in 600 consecutive renal transplant. Br J Surg. 1987;74:922–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Collado A, Camparros J, Guirado L, et al. Balloon dilation in the treatment of ureteral stenosis in kidney transplant recipients. Eur Urol. 1989;34:339–403.CrossRefGoogle Scholar
  81. 81.
    Streem SB, Novick AC, Steinmuller DR, et al. Long-term efficacy of ureteral dilation for ureteral stenosis. J Urol. 1988;140:32–5.PubMedGoogle Scholar
  82. 82.
    Voegeli DR, Crummy AB, McDermott JC, et al. Percutaneous dilation of ureteral strictures in renal transplant patients. Radiology. 1986;169:185–8.Google Scholar
  83. 83.
    Benoit G, Icard P, Bensadoun H, et al. Value of antegrade ureteral dilation for later ureteral obstruction in renal transplants. Transpl Int. 1989;2:33–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Kim JC, Banner MP, Ramchandani P, et al. Balloon dilation of ureteral strictures after renal transplantation. Radiology. 1993;186: 717–22.PubMedGoogle Scholar
  85. 85.
    Kristo B, Phelan M, Gritsch HA, Schulam P. Treatment of renal transplant ureterovesical anastomotic strictures using antegrade balloon dilation with or without holmium: YAG laser. Urology. 2003;62:631–4.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.University of Maryland School of MedicineBaltimoreUSA

Personalised recommendations